Department of Geriatrics, Yantai Yantaishan Hospital, No. 91 Jiefang Road, Yantai City, 264000, Shandong Province, China.
Department of Cardiology, Liaocheng Third People's Hospital, Liaocheng City, 252000, Shandong, China.
Appl Biochem Biotechnol. 2022 Dec;194(12):5717-5733. doi: 10.1007/s12010-022-04044-x. Epub 2022 Jul 9.
The major cause of death worldwide is atherosclerosis-related cardiovascular disease (ACD). Myrtenal was studied to determine control rats were given standard diets and a high-fat diet was given to AS model groups. Atherosclerosis-related cardiovascular disease (ACD) is globally attributed to being a predominant cause of mortality. While the beneficial effects of Myrtenal, the monoterpene from natural compounds, are increasingly being acknowledged, its anti-atherosclerotic activity has not been demonstrated clearly. The present study is proposed to determine the anti-atherosclerotic activity of Myrtenal in high-fat diet-induced atherosclerosis (AS) rat models. Control groups were maintained with standard diets, the AS model rats were provided a high-fat diet, two of the experimental groups fed with a high-fat diet were treated with Myrtenal (50 mg/kg and 100 mg/kg), and one experimental group on high-fat diet was treated with simvastatin (10 mg/kg) for 30 days. The levels of inflammatory cytokines were analyzed using kits. The lipoproteins and the lipid profile were estimated using an auto-analyzer. The atherogenic index and marker enzyme activities were also determined. Serum concentrations of 6-keto-prostaglandin F1α (6-keto-PGF1α), thromboxaneB2 (TXB2), endothelin (ET), and nitric oxide (NO) were measured. The AS model groups indicated altered lipid profile, lipoprotein content, atherogenic index, calcium levels, HMG-CoA reductase activity, collagen level, and mild mineralization indicating atherosclerosis, while the AS-induced Myrtenal-treated groups demonstrated anti-atherogenic activity. The Myrtenal-treated groups exhibited a decreased TC, TG, and LDLc levels; increased HDLc levels; and a decline in the inflammatory cytokines such as CRP, IL-1β, IL-8, and IL-18 when compared to the untreated AS rats. Furthermore, Myrtenal decreased ET, TXB2, and 6-keto-PGF1α levels indicating its anti-atherosclerotic activity. The study results thus indicate that Myrtenal modulates the lipid metabolic pathway to exert its anti-atherosclerotic activity.
全世界主要的死亡原因是与动脉粥样硬化相关的心血管疾病（ACD）。本研究旨在探讨桃金娘烯醇对高脂肪饮食诱导的动脉粥样硬化（AS）大鼠模型的抗动脉粥样硬化作用。对照组给予标准饮食，AS 模型组给予高脂肪饮食。实验组中的两组给予高脂肪饮食并分别用 50mg/kg 和 100mg/kg 的桃金娘烯醇进行治疗，另一实验组给予 10mg/kg 的辛伐他汀进行治疗，共治疗 30 天。采用试剂盒分析炎症细胞因子水平，自动分析仪估计脂蛋白和血脂谱，测定动脉粥样硬化指数和标记酶活性。还测量了血清中的 6-酮-前列腺素 F1α（6-keto-PGF1α）、血栓素 B2（TXB2）、内皮素（ET）和一氧化氮（NO）浓度。AS 模型组显示脂质谱、脂蛋白含量、动脉粥样硬化指数、钙水平、HMG-CoA 还原酶活性、胶原水平和轻度矿化改变，表明发生了动脉粥样硬化，而用桃金娘烯醇治疗的 AS 模型组则表现出抗动脉粥样硬化作用。与未治疗的 AS 大鼠相比，桃金娘烯醇治疗组的 TC、TG 和 LDLc 水平降低，HDLc 水平升高，CRP、IL-1β、IL-8 和 IL-18 等炎症细胞因子水平降低。此外，桃金娘烯醇降低了 ET、TXB2 和 6-keto-PGF1α 水平，表明其具有抗动脉粥样硬化作用。因此，研究结果表明，桃金娘烯醇通过调节脂质代谢途径发挥其抗动脉粥样硬化作用。
